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ABSTRACT
Objective: Cancer screening policies and programmes
should take account of public values and concerns.
This study sought to determine the priorities, values
and concerns of men who were ‘fully informed’ about
the benefits and harms of prostate-specific antigen
(PSA) screening; and empirically examine the value of
a community jury in eliciting public values on PSA
screening.
Setting: Community jury was convened on the Gold
Coast, Queensland (Australia) to consider PSA
screening benefits and harms, and whether
government campaigns on PSA screening should be
conducted.
Participants: 27 men (volunteers) aged 50–70 with
no personal history of prostate cancer and willing to
attend jury 6–7 April 2013: 12 were randomly allocated
to jury (11 attended).
Outcome measures: A qualitative analysis was
conducted of the jury deliberations (audio-recorded
and transcribed) to elicit the jury’s views and
recommendations. A survey determined the impact of
the jury process on participants’ individual testing
decisions compared with control group.
Results: The jury concluded governments should not
invest in programmes focused on PSA screening
directed at the public because the PSA test did not
offer sufficient reassurance or benefit and could raise
unnecessary alarm. It recommended an alternative
programme to support general practitioners to provide
patients with better quality and more consistent
information about PSA screening. After the jury,
participants were less likely to be tested in the future
compared with the controls, but around half said they
would still consider doing so.
Conclusions: The jury’s unanimous verdict about
government programmes was notable in the light of
their divergent views on whether or not they would be
screened themselves in the future. Community juries
provide valuable insights into the priorities and
concerns of men weighing up the benefits and harms
of PSA screening. It will be important to assess the
degree to which the findings are generalisable to other
settings.
INTRODUCTION
The beneﬁts and harms of prostate-speciﬁc
antigen (PSA) screening have been debated
for several decades. Based on current evi-
dence, it is possible that screening improves
survival but also leads to harms, particularly
the diagnosis and treatment of cancers that
would not otherwise become clinically appar-
ent.1–3 It was hoped that two large rando-
mised controlled mass population trials with
survival as the primary end-point would
provide a conclusive answer to the beneﬁts
and harms of screening, but the US PLCO
trial found no beneﬁt,4 possibly because a
large proportion of men in the control arm
were screened and the European ERSPC
trial showed a small reduction in prostate
cancer mortality (1 life saved for every 1055
men screened) though no reduction in all-
cause mortality.5
This equivocal evidence has led to dispar-
ate recommendations about PSA screening.
The National Screening Committee in the
UK and the US Preventative Task Force have
advised against routine PSA testing for
asymptomatic men.6 7 The American
Urological Association recommends routine
PSA screening for men between the ages of
Strengths and limitations of this study
▪ First published study of a community jury
on the topic of prostate-specific antigen (PSA)
screening.
▪ Provides in-depth analysis of informed men’s
priorities and values regarding PSA testing.
▪ Establishes the value of the community jury as a
deliberative method for engaging the public in
debates about cancer screening to elicit their
informed views on policy questions.
▪ The broader generalisability of the views and
conclusions of this jury has not yet been tested.
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55 and 69.8 9 The 2013 Prostate World Congress Mel-
bourne Consensus Statement on Prostate Cancer Testing
did not recommend routine screening, but recom-
mended that well-informed healthy men aged 50–69 be
counselled about the positive and negative aspects of
PSA testing and the ability of PSA testing ‘to reduce
their risk of metastases and prostate cancer-speciﬁc
mortality’.10
Owing to increasing recognition of the potential
harms from screening, information about screening pro-
grammes has shifted from emphasising screening uptake
to ensuring potential participants are provided with
adequate information to make an informed choice
about whether or not to be screened.11–13 This, however,
requires understanding of complex issues, such as
disease-speciﬁc mortality, avoidance of metastatic disease
and latent cancers that are indolent in nature. The com-
plexity is further compounded by the uncertainties
regarding the estimates of screening outcomes.
Moreover, the concept of potential harm from an early
detection of cancer runs counter to messages men may
have previously heard regarding the beneﬁts of early
detection. Men with a family history of prostate cancer
are particularly likely to have concerns about the bene-
ﬁts and harms from screening.
While offering evidence-based information is ethically
imperative,14 the complexities of PSA screening make
this difﬁcult to achieve within the context of the average
clinical consultation and can be burdensome for patients
and clinicians.15 Indeed some patients prefer to be
advised what to do rather than considering detailed infor-
mation about beneﬁts and harms.11 16 All recommenda-
tions on PSA testing emphasise the provision of
information and shared decision-making. We conducted
a community jury process17–19 to determine the prior-
ities, values and concerns regarding PSA screening
among men aged 50–70 who we ‘fully informed’ about
the reasons for and against screening. The jury members
were asked to deliberate evidence presented by experts
on PSA screening and invited to formulate recommenda-
tions on potential government actions. A survey using
a randomised control design was incorporated to
also determine the impact of the jury process on partici-
pants’ knowledge and individual testing intentions
(personal communication, Thomas R, Glasziou P,
Rychetnik L, et al, 2013). The protocol was registered
with the Australian and New Zealand Clinical Trials
Registry (ACTRN12612001079831).
METHOD
Community juries provide an opportunity to examine
what ‘mini-publics’ would conclude if well-informed and
supported to deliberate on a given topic.20 While various
kinds of deliberative methods exist, we adopted the com-
munity jury method as this has been successfully applied
in other settings to consider questions on breast cancer
screening.18 19
Recruitment and selection
The study participants were recruited through unpaid
news articles, one paid advertisement in a local paper,
two radio interviews and two presentations by the jury
facilitator (RT) at Rotary Club community groups. Men
were eligible to participate in the study if they were aged
between 50 and 70, had no personal history of prostate
cancer and were willing to attend an information session
on Friday night and community jury sessions on
Saturday and Sunday. We sought to recruit 12 partici-
pants to the jury: 31 men were recruited, 4 withdrew
prior to the Friday information night, and all of those
who attended the information session chose to partici-
pate in the study randomisation. The 27 participants
attending the information session were randomly allo-
cated to either the jury (n=12) or a control group
(n=15) by selecting a folded piece of paper from a con-
tainer. Members of both groups were provided with two
fact sheets about PSA screening.21 22 The jury members
were given additional summarised information to take
home,23–25 subsequently discussed as part of the jury
process.
Questions for deliberation by the community jury
At the start of the community jury process, the partici-
pants were invited to consider two questions about
potential government actions regarding PSA screening
(box 1), with the aim of ﬁnalising a group response to
these questions at the end of the second day. The terms
government ‘campaigns’ and ‘organised invitation pro-
gramme’ were purposefully left open so that the jury
members could deliberate among themselves on what
types of government action would or would not be
appropriate. The second question about an invitation
programme was asked because this had been identiﬁed
by men’s health advocacy groups as a way of matching
breast cancer screening services offered to women.
Community jury process
The community jury was conducted on the 6–7 April
2013 at Bond University, Queensland, Australia. The jury
process was informed by a previous jury conducted in
2007 to examine women’s views on mammography
screening (protocol details provided by the authors
via personal communication).19 Day 1 focused on inter-
rogating the expert evidence and day 2 on jury delibera-
tions. On the ﬁrst day of the PSA screening jury, the
Box 1 Questions posed to the jury about potential
government action
▸ Should government campaigns be provided (on prostate-
specific antigen screening) and if so, what information should
be included in those campaigns?
▸ What do you as a group of men think about a government
organised invitation programme for testing for prostate
cancer?
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participants heard presentations from the following
experts:
Professor Jim Dickinson, University of Calgary (visiting
scholar at Bond University at the time of the jury)
who provided information about the prostate, prostate
cancer and the methods used to diagnose and treat
prostate cancer.
Professor Robert (Frank) Gardiner, Professor of
Urology, University of Queensland who presented
information in support of selective screening of
informed men and additional information on prostate
cancer diagnosis, prognosis and treatment (RG).
Professor Paul Glasziou, Director, Research Centre for
Evidence-based Practice, Bond University who pre-
sented on why he did not recommend screening
(PG).
The three expert sessions ran for approximately
40 min each, followed by questions from the jury. Each
session was followed by a facilitated discussion to elicit
the men’s reﬂections and responses to the information
presented. Any further questions arising from the facili-
tated discussions were noted and addressed on day 2.
Expert witnesses RG and PG were introduced to the jury
as members of the research team. Other than to present
evidence and answer the jury’s questions, the expert wit-
nesses did not attend any of the jury deliberations.
At the start of day 2, the jury again reﬂected on the
issues raised from day 1 and identiﬁed any ﬁnal ques-
tions for the experts, which were answered via a speaker-
phone. The jury then deliberated without a facilitator
present on the two questions about potential govern-
ment action on PSA screening (box 1). Finally the jury’s
conclusions and recommendations were recorded in a
facilitated (LR) feedback session at the end of day 2.
Data collection and analysis
The complete community jury process was audio-
recorded and transcribed, including the experts’ presen-
tations and Q&A sessions, all participant deliberations
(facilitated and unfacilitated) and the ﬁnal compilation
of the jury’s response and recommendations about gov-
ernment action on PSA screening. The jury’s recom-
mendations were compiled onto a ﬂipchart and each
point was reviewed and corrected as required by the par-
ticipants to ensure that the summary of the jury’s verdict
accurately represented the group’s deliberations and
conclusions. In addition, two researchers (LR and GM)
observed the jury process to compile ﬁeld notes and
provide feedback to the primary facilitator on group
process and participant interactions.
The qualitative ﬁndings were derived from an analysis
of the full transcripts of the jury process. The text was
analysed in a multistage process comprising detailed
descriptive and conceptual coding followed by the prep-
aration of analytical synthesis memos26 on topics such as
reasons for attending jury, important concerns about
PSA testing, areas of consensus, areas of divergence and
factors inﬂuencing personal decisions. Findings on the
jury process were also derived from the transcripts, plus
from the observational ﬁeld notes and all researchers’
reﬂections documented in postjury memos and email
exchanges. The validity, relevance and interpretation of
the ﬁndings were reviewed in research team discussions.
The qualitative ﬁndings are summarised under ‘reasons
for attending the jury’, ‘core values related to PSA
screening’ and boxes 2–4. The jury’s recommendations
and rationale for their ﬁnal verdict are summarised in
the section ‘community jury verdict on community-level
questions’.
The jury participants completed two written surveys;
one before the jury (Friday evening) and one immedi-
ately after the jury (Sunday lunchtime). The control
group also completed the ﬁrst survey on Friday and the
second one by mail. The ﬁrst survey collected demo-
graphic data and included questions on previous PSA
tests and intention of getting tested for prostate cancer
in the future if they had no symptoms (scale 0 ‘not at
all’ to 10 ‘absolutely’). It also included questions on
sources of information about prostate cancer testing
(checklist of options) and how informed the men per-
ceived themselves to be about the beneﬁts and harms of
prostate cancer testing (scale 0 ‘not at all’ to 4 ‘very’).
The second survey re-examined the men’s perceptions
of how informed they considered themselves and their
intention of having PSA screening in the future if they
had no symptoms (analysed by linear regression27 and
repeated measures analysis of variance).
RESULTS
Description of study participants
Of the 12 men randomised to the community jury, 1
withdrew prior to Saturday and another was unwell and
did not return on Sunday. Thus 11 men contributed to
the discussions on day 1, and 10 men contributed to the
Box 2 Information identified by the men as important but
unexpected or surprising
▸ Prevalence of prostate cancer among older men (higher than
expected).
▸ Progression of many prostate cancers (slower than expected).
▸ That prostate cancers may not have any clinical/health implica-
tions (unexpected).
▸ Scale of prostate-specific antigen (PSA) test levels and thus
what it means to have ‘raised’ PSA levels (scale greater than
expected).
▸ Degree of uncertainty about correlations between PSA test
results and risk of cancer (higher than expected, some
unaware of benign hyperplasia or other causes of raised PSA
levels).
▸ Treatment side-effects such as impotence and incontinence
(higher than expected).
▸ Notion of PSA testing as a matter of individual choice, rather
than indicated by evidence or the ‘right’ thing to do
(unexpected).
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ﬁnal jury verdict. All 11 participants completed the
prejury and postjury questionnaire.
Demographics, PSA screening information sources and prior
testing
The 11 jury participants were aged between 53 and
68 years (mean age=61, SD=5.04). Two participants had
postgraduate qualiﬁcations (18%), three were university
or technical college graduates (27%), four had some
university or technical college experience (37%) and
two had a high school education or less (18%). Prior to
the jury, the men reported obtaining information from a
variety of sources; general practitioners (GPs) were the
mostly common source of information (nominated by 8
men), followed by family and friends (nominated by 5),
the Internet and media (nominated by 4 men each;
table 1). Ten men on the jury reported having previously
had a blood test for prostate cancer. Of these, 2 had
been tested once (18%), 3 had been tested twice (27%),
the remaining 5 had each been tested on 3, 6, 7, 8 and
12 occasions, respectively (9% each).
Reasons for attending the jury
The men said they agreed to participate primarily to
learn more about prostate cancer and PSA testing.
Several noted they wanted to become more aware and
informed about their health, that men generally were
Table 1 Reported sources of information on testing for
prostate cancer prior to jury
N=11 Per cent
General practitioner 8 73
Family and friends 5 46
Internet 4 36
The media 4 36
Other (urologist/surgeon) 2 18
Other (hospital seminar) 1 9
Never looked for information 2 18
NB: Men could endorse more than one category.
Box 4 Some differences of opinion
The men on the jury expressed some differences of opinion on
the following points:
▸ Personal decisions on whether or not it is better to have the
test
‘..is there a test for lung cancer, heart disease, colon cancer,
dementia, diabetes? I’d be getting tested for all those long
before I’d get a bloody prostate test’.
▸ The importance of impotence and incontinence against the
risk of death
P1 ‘I would have thought longevity at 70 was more important
than sexual activity.’
P2 ‘Oh it depends’
P3 ‘Probably a lot of men..’
P2 ‘Horses for courses, I think’
P1 ‘I’m just saying, who would die over sex?’
▸ Whether or not (degree to which) men in general will want all
of the information provided to the community jury—but group
agreed the information should be available for those who do
want it
▸ Whether or not they want doctors to advise/tell them what to
do, or whether it is up to each man to make their own
decision
▸ Whether or not it had been a good idea for them to ask the
expert presenters what their personal decisions were about
prostate-specific antigen (PSA) testing. Most said they wanted
to know, one man said the responses swayed his own view
too much and he would have preferred not to know (The
group asked the presenters whether or not they had had a
PSA test: one had, two had not)
Box 3 Points of general consensus
In general the men on the jury agreed on the following issues
and points:
▸ Need for better and more standardised information; particu-
larly more about the limitations, pros and cons of prostate-
specific antigen (PSA) testing. The group particularly liked a
figure based on available trial data that reported the number of
men harmed (side-effects of treatment and associated psycho-
logical effects) and the 1 potential life saved per 1000 men
screened.
▸ Need for general practitioners (GPs) to advise men of why
PSA testing is not recommended by their guidelines.
▸ Importance of men taking responsibility and being able to
make their own informed personal decisions about testing.
▸ Need for GPs to provide information about what it means to
have a raised PSA test: ‘if she’d talked to me just briefly about
these things in terms of the imprecise nature of the whole
screening process, I would have been a lot better off and felt a
lot less stressed on leaving that day.’
▸ Valuing the availability of the test for those who want it.
▸ Valuing the time to ask questions and discuss issues with
experts.
▸ Obtaining information from an independent source, with no
financial or other vested interests.
▸ Not promoting PSA testing to the general population given the
current uncertain status of the evidence and likelihood of find-
ings of latent cancers if you look for them.
▸ Avoiding unnecessary anxiety among their family, friends and
the community associated with promoting PSA testing when
considering the uncertainty of the PSA test and not knowing
how to interpret the results.
▸ Directing funds from screening towards generating better diag-
nostic tests, predictors to distinguish aggressive versus indo-
lent cancers and safer treatment options.
▸ Importance of not wasting government funds on doing waste-
ful testing, importance of considering costs and benefits of
government-funded programmes, not focusing on something
if it is not sufficiently important as a health concern or risk ‘In
most people it isn’t an issue, why make it an issue’.
▸ Important to prioritise those things that are more likely to
impact on men’s health.
▸ Perception that government sponsored information sent dir-
ectly to public is often thrown out or ignored (gave example
of colorectal cancer screening material).
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not very good at this, and they had decided to change
their previous ‘she’ll be right’ attitude. ‘I guess having
reached the age of 60, realising that we’re not all bullet-
proof...’ Group discussions also identiﬁed the role of
wives and doctors in encouraging a more preventive
approach to healthcare. A majority of the men said the
jury was an opportunity to learn about a topic on which
they knew very little, heard conﬂicting messages and
reports on what to do or had ‘snippets of information
each way’ for and against testing. One man revealed he
was undergoing regular monitoring of his PSA levels by
an urologist after his ﬁrst PSA test had been ordered by
a GP without his knowledge when he had attended for a
cholesterol check. One other man said he had prior uro-
logical symptoms but had been cleared of signiﬁcant
disease. Several participants reported the experiences of
family and/or friends with prostate cancer that resulted
in variable outcomes, including a number of premature
deaths.
Core values related to PSA screening
The men discussed their own and others’ experiences of
PSA testing and compared the evidence presented at
the jury to the information and advice they received
from GPs and other doctors. In their reﬂections, they
particularly noted how much of the evidence presented
by the experts was unfamiliar and surprising for them;
particularly the likelihood of a raised PSA result, the
uncertainty about what raised PSA levels mean, and the
high prevalence of prostate cancer with no clinical sig-
niﬁcance. The issues that men identiﬁed as important
information but unexpected or surprising are sum-
marised in box 2.
Overall the group concluded that given the uncertain
evidence and divergent opinions about screening, PSA
testing was an individual choice for which they needed
to take personal responsibility. For some in the group,
the idea that it was acceptable to chose not to have a
PSA test—even if offered or advised to have one—was a
revelation as they had previously interpreted such a
choice as avoidance or as being ‘slack’ about their
health:
I was of the opinion when I came in that every man over
60 should be screened as a matter of fact, but now
I think I’ve changed my ideas, that it’s a personal
decision
The group also concluded that the poor quality or
lack of information provided by GPs did not currently
support men in making informed decisions. Thus one
of the most discussed concerns among the participants
was the variable and inconsistent advice provided by
their GPs; as well as the inadequate or conﬂicting infor-
mation and messages about PSA testing from different
doctors, media campaigns and other sources. The points
reﬂecting general group consensus during deliberations
are summarised in box 3, while some differences in
opinion are summarised in box 4.
The men were generally concerned that GPs were not
following the guidelines of their College,24 and that it
depended on which GP they went to as to whether or
not they were advised to have a PSA test, and what (if
any) information was provided when a test was ordered.
For example, the jury shared experiences of their
doctors requesting PSA tests without informing the
patient, for example at a time when another blood test
was also requested. For one participant this experience
resulted in signiﬁcant personal regret and ongoing
anxiety associated with continued monitoring ‘If only I
hadn’t gone for the cholesterol test in 2007’. Conversely,
another man had been refused a PSA test even though
he speciﬁcally asked for it and he changed his doctor as
a result. The group also shared their own and others’
experiences of inconsistency in how different doctors
interpret PSA test results (eg, what degree of elevated
PSA levels were perceived to be ok or expected); and
how urologists varied in what they recommended once
PSA levels were found to be raised (eg, biopsy vs no
biopsy, surgery or monitoring). The men also worried
about the lack of standardisation of testing procedures,
for example, whether or not men were advised to
abstain from sexual activity before testing.
In addition to the core concerns about the available
information and advice, the men were also concerned
about the relationship between PSA testing and anxiety
and depression. On deliberating the evidence many con-
cluded that the apparent uncertainties in the science of
PSA testing primarily mean that a raised PSA test result
(or subsequent diagnosis of prostate cancer) was a
source of signiﬁcant anxiety without offering any valu-
able information on how to act:
All they’re going to say is yeah, you’ve got it. You’re going
to worry for the next 15 years, is it bigger, is it smaller,
am I going to get tested again?
After deliberating the evidence most of the jury con-
cluded that having a PSA test was a genuinely difﬁcult
and personal choice. As a result, several of the men
expressed concerns about the active promotion of PSA
testing by some doctors and through public campaigns
and charities such as ‘Movember’.28 This was considered
by some to be deceptive in the light of current uncer-
tainty about what PSA results mean, the lack of available
technologies to differentiate aggressive versus indolent
cancers and the lack of satisfactory/safe treatment
options for prostate cancer. The jury’s discussions
focused on the importance of not harming men
through unnecessary investigations and treatments,
including those for whom the cancer will never pro-
gress, or for whom other conditions would kill them
ﬁrst. Several in the group agreed that for many of their
peers other emerging health problems, including
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cardiovascular disease, diabetes or mental health were
more important concerns than prostate cancer.
Community jury verdict on community-level questions
The jury’s responses to the community-level questions
(box 1) on potential government action on PSA screen-
ing for prostate cancer were as follows (ﬁnal day, n=10):
Recommended against any government campaigns
aimed at the public on the topic of PSA screening.
This included a recommendation against any orga-
nised invitation programme for prostate cancer screen-
ing (unanimous).
Proposed instead a campaign targeting GPs to assist
GPs to provide better quality and more consistent
information to their patients about PSA testing for
prostate cancer. The men particularly wanted GPs to
provide to patients information on: the unreliable
nature of the PSA test, prevalence of raised PSA levels
in older men, prevalence of prostate cancer relative to
risk of death, screening outcomes (rates/1000 men
screened), treatment side-effects (rates; unanimous).
Proposed that facts about PSA screening for prostate
cancer, including that it is not currently recom-
mended in Australian GP practice guidelines and an
explanation of why, could be provided directly to the
public if it was included as part of a broader ‘men’s
health’ information programme or website. The latter
was preferred to identifying PSA screening as a tar-
geted priority issue (unanimous).
Jury’s rationale for final verdict
The jury’s primary concern was that any public cam-
paign focused on PSA testing for prostate cancer had
potential to cause anxiety and alarm among the majority
of men who did not need to be concerned about pros-
tate cancer. Other reasons given by the jury for why they
believed a government campaign on PSA screening was
not warranted were nominated as follows:
▸ Contradictory nature of the current status of the
science;
▸ Unreliable nature of the PSA test;
▸ Low incidence of mortality from prostate cancer;
▸ High cost of such a campaign;
▸ Funds required are more likely to be better used on
research into the diagnosis and treatment of prostate
cancer.
‘We don’t want the government to invite us or our
mates to come along and get tested. We don’t want that
to happen because we don’t want our mates to worry.
We don’t want people to make a fuss, we don’t want our
government to waste our money.’
Individual-level PSA testing decisions
After the jury the men considered themselves better
informed about the beneﬁts and harms of prostate
cancer testing compared with prior to the jury (F=14.34,
p=0.004; table 2). This improvement was signiﬁcantly
greater than in the control group (F=7.3, p=0.01).
Following the jury, the men also decreased their inten-
tion to be screened for prostate cancer in future com-
pared with their intentions prior to the jury (F=8.83,
p=0.014; table 2). The jury also scored 4.3 points lower
on the postjury intention to test scale than the controls
(p=0.001; table 3). At the end of the jury, ﬁve men
reported they were ‘not at all’ likely to get tested in the
future if they had no symptoms, whereas six would con-
sider it—and of these, four were more likely than not to
do so (ie, scored ≥5 on scale 0–10; table 4).
DISCUSSION
Government policies must take account of public values
and concerns. Deliberative methods such as community
juries are well suited to support evidence-informed
public engagement on screening policies and pro-
grammes.17 In this study, a group of men aged between
50 and 70, after deliberating on the beneﬁts and harms
of PSA screening, concluded that governments should
not invest in any organised programmes focused on PSA
screening that were directed at the public. They deter-
mined that the PSA test did not offer sufﬁcient reassur-
ance or beneﬁt to warrant a public campaign, and that
such an approach would raise unnecessary alarm about
prostate cancer. The jury did however want men to con-
tinue to have access to the test and to be able to make
an informed choice about whether or not to be
screened. They recommended an alternative govern-
ment programme aimed at supporting GPs to provide
patients with better quality and more consistent informa-
tion about the beneﬁts and harms of PSA screening.
The jury’s verdict on public campaigns was not antici-
pated by the research team; rather we expected that if
anything, the jury may identify a need for a public educa-
tion campaign on PSA screening. The jury
Table 2 Reported changes compare pre–post jury measures: perception of how well informed and how likely to test for
prostate cancer
Comparison of continuous variables at preassessment and postassessment (N=11)
Preassessment Postassessment
Mean SD Mean SD F p Value
Informed about harms and benefits 2.0 1.2 3.6 0.5 14.34 0.004
Likely to test for prostate cancer 7.3 3.5 3.5 4.1 8.83 0.014
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overwhelmingly reported being previously unaware of the
relative beneﬁts and harms of screening, and their prefer-
ence for obtaining such information from their doctor.
The option of a government programme targeting GPs
was nominated by the jury themselves, reﬂecting their
primary concern about the lack of information provided
by their doctors and their shared experiences of incon-
sistent PSA screening advice. The ﬁndings indicate the
facilitation process had been open and non-directive.
Community juries are not intended to be representa-
tive of the wider population in the statistical sense;
rather they offer valuable insights on the informed views
and conclusions of a ‘mini-public’.20 This study provides
valuable insights into the concerns and priorities with
regard to PSA testing among men aged 50–70; both as
individuals interested in PSA testing, and as citizens
invited to weigh community beneﬁts and harms. The
jury’s unanimous verdict about government programmes
was notable in the light of the men’s divergent views on
whether or not they would get tested again in future
themselves if they had no symptoms. These ﬁndings
support other literature indicating community juries
delineate and rise above individual decisions to consider
higher order questions about the common good.29
While the men’s personal interest in PSA testing did not
appear to hinder their willingness and ability to consider
more broadly its relative value for their community,
other kinds of public may have reached different conclu-
sions. For example, a majority of the jury had been pre-
viously tested, and while the proportion of Australian
men who have ever had a PSA test is unknown, approxi-
mately 20% of Australian men aged 45–74 years had
screening PSA tests between 2010 and 2011.30 In other
countries such as the USA the participation in PSA
testing is relatively high; around 50% among men aged
60–74.31 The impact of these differences on the deliber-
ation and conclusions of a jury on PSA testing is cur-
rently unknown.
It will be important therefore to repeat the delibera-
tive process with other juries, both to examine the views
of different publics, and to assess the generalisability of
the ﬁndings to other parts of Australia and other coun-
tries with different information and services. Similarly, it
will be relevant to assess the potential impact on jury
deliberations or conclusions of varying aspects of the
community jury process, such as the method of recruit-
ing participants or of presenting evidence. Different
publics could include men of different ages, a mixed
group of men aged 50–70 and partners or other family
members (particularly as the men noted the inﬂuence
of partners on their health behaviours) or a random
sample from the electoral roll—although these methods
are still affected by respondents’ level of interest. Other
forms of evidence could include the personal stories of
men affected by prostate cancer and/or the side-effects
of treatment, or those without a diagnosis but whose
PSA level is being monitored. Finally, it will also be valu-
able to compare the effectiveness of eliciting public
values about cancer screening using other deliberative
methods.32
The recent Australian NHMRC Information for Health
Practitioners: Prostate Speciﬁc Antigen (PSA) Testing for
Prostate Cancer in Asymptomatic Men33 provides guidance
on communicating the evidence on the beneﬁts and
harms of PSA screening to asymptomatic men. It will be
imperative to identify effective mechanisms to facilitate
implementation of this guidance within Australian
general practice. It will be also important to better align
and even regulate the messages about PSA testing that
are promoted in media campaigns by prostate cancer
charities and other non-government organisations and
special interest groups so that more consistent informa-
tion and advice is presented.
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